The in vitro and in vivo effects of clofazimine on the motility of neutrophils and transformation of lymphocytes from normal individuals.

The effects of clofazimine on neutrophil motility to endotoxin­ activated serum and mitogen-induced lymphocyte transformation of leucocytes from normal individuals in vitro, and after ingestion of clofaz­ imine by normal adult volunteers have been assesse d . Clofazimine caused a progressive dose-depen dent inhibition of neutrophil motility and of lymphocyte transformation in vitro. Ingestion of the drug by normal volunteers was accompanied by decreased neutrophil motility and lympho­ cyte transformation to mitogens . These findings suggest that the anti­ inflammatory properties of clofazimine are related to inhibition of these cellular immune functions .

[1]  R. Anderson,et al.  In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy , 1981, Antimicrobial Agents and Chemotherapy.

[2]  R. Anderson,et al.  Changes in neutrophil motility accompanying dapsone and rifampicin therapy. , 1981, Leprosy review.

[3]  H. Jacob,et al.  Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. , 1978, The Journal of clinical investigation.

[4]  W. Bullock,et al.  Quantitative and qualitative studies of the local cellular exudative response in leprosy. , 1974, Journal of the Reticuloendothelial Society.

[5]  S. Frøland,et al.  Evidence that the Mechanism of Immunological Tolerance (‘Central Failure’) Is Operative in the Lack of Host Resistance in Lepromatous Leprosy , 1972, Scandinavian journal of immunology.

[6]  R. Pfaltzgraff.  The control of neuritis in leprosy with clofazimine. , 1972, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[7]  P. Wilkinson.  Chemotaxis of Phagocytic Cells Towards Proteins: The Effect of Protein Denaturation , 1971 .

[8]  W. Vischer.  The experimental properties of G 30 320 (B 663)--a new anti-leprotic agent. , 1969, Leprosy review.

[9]  F. Imkamp.  A treatment of corticosteroid-dependent lepromatous patients in persistent erythema nodosum leprosum. A clinical evaluation of G.30320 (B663). , 1968, Leprosy review.